Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
The company, a leading manufacturer of CPAP machines used to treat sleep apnea, faces a nuanced challenge from GLP-1-based medications. The core issue: obesity drives the vast majority of obstructive sleep apnea cases, with 70-90% of sufferers experiencing the condition due to excess weight. As patients lose weight through GLP-1 treatments, their need for breathing assistance devices may disappear entirely.
Source Fool.com
Resmed Inc. Stock
€191.35
-1.490%
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Resmed Inc..
With a target price of 256 € there is a positive potential of 33.79% for Resmed Inc. compared to the current price of 191.35 €.
